GlaxoSmithKline has struck a three-way agreement worth $16bn with Novartis to reorganise their businesses. Lex's Joseph Cotterill and Robert Armstrong discuss whether the reorganisation aids a prime objective of drugmakers: selling more drugs.
For more video content from the Financial Times, visit
Subscribe to the Financial Times on YouTube;
Comments
Post a Comment